The long-term objective of this revision application is to test hypotheses that overall anticholinergic (AC) medication exposure is associated with poor cognitive and physical performance outcomes in older adults using a novel and comprehensive assessment of AC exposure. The current paradigm is that AC medication use has reversible adverse effects on cognition, but this assumption has been challenged suggesting more detrimental permanent effects.
The Specific Aims are:
Aim 1 : Determine whether cumulative and long-term AC burden is associated with: (1.a.) increased incidence of all-cause dementia or Alzheimer's disease (AD);and (1.b.) higher burden of neuropathological markers of dementia or AD (neuritic plaques, neurofibrillary tangles, amyloid angiopathy);
Aim 2 : Determine whether current anticholinergic burden is associated with greater decline in physical performance (gait speed, composite score of lower extremity function);
Aim 3 : Establish a system and infrastructure for data resource sharing through transfer of biospecimens and data using the established procedure of the National Cell Repository for Alzheimer's Disease (NCRAD) and continue our active collaboration with the Alzheimer's Disease Genetics Consortium (ADGC). This application will utilize the Adult Changes in Thought (ACT) study which is a 17 year longitudinal study of risk factors for incident dementia. ACT has enrolled over 4000 subjects from Group Health, a large integrated health maintenance organization. The ACT study is a unique data resource;it provides a community-based cohort with longitudinal objective assessments (every 2 years) of physical and cognitive function, autopsy data for examination of neuropathological correlates of dementia, and high quality exposure information from automated pharmacy records extending back 15 years prior to ACT study baseline. The availability of detailed automated pharmacy data will allow us to significantly improve the quantification of AC use over prior studies by our ability to examine cumulative long-term AC exposure and to quantify dose and duration of each AC medication.

Public Health Relevance

Up to 25% of older adults are using AC drugs. Clinical practice would be significantly impacted if we find that long-term AC use is associated with a higher risk for dementia. It would provide a compelling reason to minimize long-term AC use and could pave the way to develop focused interventions to reduce AC drug use. This proposal will also enhance genetic and other data sharing from one of the most important ongoing studies of aging in the world

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AG006781-24S1A1
Application #
8293814
Study Section
National Institute on Aging Initial Review Group (NIA)
Program Officer
Anderson, Dallas
Project Start
1986-09-30
Project End
2014-08-31
Budget Start
2012-04-01
Budget End
2012-08-31
Support Year
24
Fiscal Year
2012
Total Cost
$128,289
Indirect Cost
$41,153
Name
Group Health Cooperative
Department
Type
DUNS #
078198520
City
Seattle
State
WA
Country
United States
Zip Code
98101
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50
Cholerton, Brenna; Larson, Eric B; Quinn, Joseph F et al. (2016) Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 186:500-6
Jackson, Michael L; Walker, Rod; Lee, Sei et al. (2016) Predicting 2-Year Risk of Developing Pneumonia in Older Adults without Dementia. J Am Geriatr Soc 64:1439-47
Crane, Paul K; Gibbons, Laura E; Dams-O'Connor, Kristen et al. (2016) Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol 73:1062-9
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21
Flanagan, Margaret; Larson, Eric B; Latimer, Caitlin S et al. (2016) Clinical-pathologic correlations in vascular cognitive impairment and dementia. Biochim Biophys Acta 1862:945-51
Crane, Paul K; Walker, Rod L; Sonnen, Joshua et al. (2016) Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes. Neurobiol Aging 48:72-82
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20
Toledo, Jon B; Gopal, Pallavi; Raible, Kevin et al. (2016) Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathol 131:393-409
Van Driest, Sara L; Wells, Quinn S; Stallings, Sarah et al. (2016) Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. JAMA 315:47-57

Showing the most recent 10 out of 234 publications